Hyrimoz FDA Approval History
Last updated by Judith Stewart, BPharm on April 30, 2025.
FDA Approved: Yes (First approved October 30, 2018)
Brand name: Hyrimoz
Generic name: adalimumab-adaz
Dosage form: Injection
Company: Sandoz Inc.
Treatment for: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Ulcerative Colitis, Plaque Psoriasis, Hidradenitis Suppurativa, Uveitis
Hyrimoz (adalimumab-adaz) is an anti-TNF-α monoclonal antibody biosimilar/interchangeable to Humira, approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
- Hyrimoz is indicated for the treatment of:
- Rheumatoid Arthritis (RA): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.
- Juvenile Idiopathic Arthritis (JIA): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
- Psoriatic Arthritis: reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA.
- Ankylosing Spondylitis (AS): reducing signs and symptoms in adult patients with active AS.
- Crohn’s Disease (CD): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- Ulcerative Colitis (UC): treatment of moderately to severely active ulcerative colitis in adult patients.
Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
- Plaque Psoriasis (Ps): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
- Hidradenitis Suppurativa (HS): treatment of moderate to severe hidradenitis suppurativa in adult patients.
- Uveitis (UV): treatment of non-infectious intermediate, posterior, and panuveitis in adults. - Hyrimoz is approved in the following dosage forms:
Product Presentation Strength Biosimilar / Interchangeable Pre-Filled Syringe 10 mg / 0.1 mL Interchangeable Pre-Filled Syringe 10 mg / 0.2 mL Interchangeable Pre-Filled Syringe 20 mg / 0.2 mL Interchangeable Pre-Filled Syringe 20 mg / 0.4 mL Interchangeable Pre-Filled Syringe 40 mg / 0.4 mL Biosimilar Pre-Filled Syringe 40 mg / 0.8 mL Interchangeable Pre-Filled Syringe 80 mg / 0.8 mL Interchangeable Autoinjector 40 mg / 0.4 mL Biosimilar Autoinjector 40 mg / 0.8 mL Biosimilar Autoinjector 80 mg / 0.8 mL Biosimilar - Hyrimoz is administered via subcutaneous injection.
- The FDA approval of Hyrimoz was based on analytical, nonclinical, pharmacokinetic and clinical data supporting biosimilarity to the reference product Humira. Safety and immunogenicity were also comparable.
- Hyrimoz comes with a Boxed Warning alerting health care professionals and patients of the increased risk of serious infections and malignancies.
- The most common reported side effects include infections (including upper respiratory, sinusitis), injection site reactions, headache, and rash.
- Hyrimoz is the third FDA-approved adalimumab biosimilar, following the approvals of Amjevita (adalimumab-atto) in 2016, and Cyltezo (adalimumab-adbm) in 2017.
Development timeline for Hyrimoz
| Date | Article |
|---|---|
| May 8, 2024 | Approval Select Strengths of Sandoz Biosimilar Hyrimoz Granted Interchangeability by FDA |
| Mar 21, 2023 | Approval Sandoz Receives US FDA Approval for Biosimilar Hyrimoz (adalimumab-adaz) High-Concentration Formulation |
| Oct 31, 2018 | Approval FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.